One CRISPR treatment cut “bad” cholesterol in half for a full year

AI Summary

An experimental CRISPR therapy has successfully reduced LDL cholesterol and triglycerides by approximately half in patients with difficult-to-treat lipid disorders, with effects lasting for at least one year. The highest dose achieved a 52.5% reduction in LDL and 47.8% in triglycerides.

A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year later, with the highest dose lowering LDL by 52.5% and triglycerides by 47.8%.